Patent application number | Description | Published |
20090081199 | Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof - Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders. | 03-26-2009 |
20090214557 | BIOLOGICALLY ACTIVE ANTIBODIES RECOGNIZING A CELL SURFACE MOLECULE SELECTIVELY EXPRESSED ON LIVING MOUSE NATURAL TYPE ONE (I) INTERFERON PRODUCING CELLS - An isolated and characterized monoclonal antibody (“440 | 08-27-2009 |
20100305306 | NOVEL RECEPTOR TREM (TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS) AND USES THEREOF - Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders. | 12-02-2010 |
20100306863 | SCREENING, THERAPY AND DIAGNOSIS - A TREM-1 ligand is identified. This allows various derivatives to be provided/identified that are capable of binding to the TREM-1 receptor. The TREM-1 ligand or the derivatives can be used in screening for drugs/drug candidates. Substances that block or reduce binding of the TREM-1 ligand/derivative to a TREM-1 receptor may be useful for treating sepsis, particularly sepsis of bacterial or fungal origin. Antibodies to the ligand may be useful in diagnosing sepsis, particularly sepsis of bacterial or fungal origin. | 12-02-2010 |
20100310560 | Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof - Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR | 12-09-2010 |
20130028901 | NOVEL RECEPTOR TREM (TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS) AND USES THEREOF - Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders. | 01-31-2013 |
20130150559 | NOVEL RECEPTOR TREM (TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS) AND USES THEREOF - Novel activating receptors of the lg super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders. | 06-13-2013 |
Patent application number | Description | Published |
20100330539 | PERIODONTAL TREATMENT SYSTEM AND METHOD - Methods and apparatuses for treating a root canal in a tooth or hard and/or soft tissue within a tooth and surrounding tissues by pulsing a laser light into a reservoir, preferably after introducing liquid fluid into the reservoir, so as to disintegrate, separate, or otherwise neutralize pulp, plaque, calculus, and/or bacteria within and adjacent the fluid reservoir without elevating the temperature of any of the dentin, tooth, bones, gums, other soft tissues, other hard tissues, and any other adjacent tissue more than about 5° C. | 12-30-2010 |
20110269099 | DENTAL AND MEDICAL TREATMENTS AND PROCEDURES - A method treating a root canal in a tooth by introducing into the pulp chamber of a tooth and pulsing a laser light into the fluid reservoir so as to disintegrate pulp within the root canal without generation of any significant heat in said liquid fluid so as to avoid elevating the temperature of any of the dentin, tooth, or other adjacent tissue more than about 5° C. | 11-03-2011 |
20130143180 | PERIODONTAL TREATMENT SYSTEM AND METHOD - Methods and apparatuses for treating a root canal in a tooth or hard and/or soft tissue within a tooth and surrounding tissues by pulsing a laser light into a reservoir, preferably after introducing liquid fluid into the reservoir, so as to disintegrate, separate, or otherwise neutralize pulp, plaque, calculus, and/or bacteria within and adjacent the fluid reservoir without elevating the temperature of any of the dentin, tooth, bones, gums, other soft tissues, other hard tissues, and any other adjacent tissue more than about 5° C. | 06-06-2013 |
20140087333 | PERIODONTAL TREATMENT SYSTEM AND METHOD - Methods and apparatuses for treating a root canal in a tooth or hard and/or soft tissue within a tooth and surrounding tissues by pulsing a laser light into a reservoir, preferably after introducing liquid fluid into the reservoir, so as to disintegrate, separate, or otherwise neutralize pulp, plaque, calculus, and/or bacteria within and adjacent the fluid reservoir without elevating the temperature of any of the dentin, tooth, bones, gums, other soft tissues, other hard tissues, and any other adjacent tissue more than about 5° C. | 03-27-2014 |
20140220511 | PERIODONTAL TREATMENT SYSTEM AND METHOD - The specification discloses embodiments and other information concerning methods, systems, and apparatus in accordance with aspects of the subject invention for treating diseased root canals in teeth and other dental condition, such as periodontitis and the like wherein a laser light is pulsed from a laser fiber optic tip into liquid contained in a reservoir or other space within the canal, periodontal sulcus/pocket, or other dental space immersing the area in need of treatment so as to disintegrate, separate, or otherwise neutralize pulp, plaque, calculus, bacteria, and other microbes, thus annihilating and particleizing undesirable material within the liquid in the reservoir by the action of relatively intense, photoacoustic micro-pressure waves propagating throughout the liquid as a result of the laser light pulses emitted into the liquid from the tip, thereby enabling easy removal of the particles by finely dispersing the same in the liquid and then flushing the particle-laden liquid from the area by hydraulic swirling actions associated with the pulsing light and through ensuing antiseptic rinses, all without elevating the temperature of nearby dentin, tooth, bones, gums, and/or other soft/hard adjacent tissues more than about 5° C. so as to avoid or eliminate harmful effects of localized heating of the same. | 08-07-2014 |
Patent application number | Description | Published |
20080277545 | Medical device clamp - A medical instrument device interconnection system decreases the vibrational effects on a hospital pole. The medical device is contained in a case and the case has a first clamping member, a first biasing apparatus, a second clamping member, a second biasing apparatus, and a pole receiving trench. Each clamping member has a preferred position, an attachment position and a maximum tension position. In the preferred position the respective biasing members position the respective clamping member's distal end as close to each other as possible which inhibits a conventional hospital pole from entering the pole receiving trench. To obtain the maximum tension position, the person positioning the medical instrument device on the hospital pole aligns the pole receiving trench with the hospital pole so the hospital pole contacts the clamping members' exterior surface in the preferred position. The person raises the device in relation to the pole which causes the clamping members to rotate and expose the pole receiving trench. Once the hospital pole enters the pole receiving trench the respective biasing apparatus on each clamping member has the respective clamping members revert toward the preferred position. The preferred position cannot be obtained because the hospital pole in the pole receiving trench inhibits the clamping members from reverting to that position. Instead the clamping members are in the attachment position after the medical instrument device is lowered a little in relation to the hospital pole to obtain the maximum force in the attachment position. Collectively the biasing apparatuses through the clamping members in the attachment position provide more force to the hospital pole than the weight of the medical instrument device. That way the medical instrument device remains attached to the hospital pole and due to the flexible biasing apparatuses the device's vibration is suppressed while attached to the hospital pole. | 11-13-2008 |
20080281387 | Medical Device Clamp - A medical instrument device interconnection system decreases the vibrational effects on a hospital pole. The medical device is contained in a case and the case has a first clamping member, a first biasing apparatus, a second clamping member, a second biasing apparatus, and a pole receiving trench. Each clamping member has a preferred position, an attachment position and a maximum tension position. In the preferred position the respective biasing members position the respective clamping member's distal end as close to each other as possible which inhibits a conventional hospital pole from entering the pole receiving trench. To obtain the maximum tension position, the person positioning the medical instrument device on the hospital pole aligns the pole receiving trench with the hospital pole so the hospital pole contacts the clamping members' exterior surface in the preferred position. The person raises the device in relation to the pole which causes the clamping members to rotate and expose the pole receiving trench. Once the hospital pole enters the pole receiving trench the respective biasing apparatus on each clamping member has the respective clamping members revert toward the preferred position. The preferred position cannot be obtained because the hospital pole in the pole receiving trench inhibits the clamping members from reverting to that position. Instead the clamping members are in the attachment position after the medical instrument device is lowered a little in relation to the hospital pole to obtain the maximum force in the attachment position. Collectively the biasing apparatuses through the clamping members in the attachment position provide more force to the hospital pole than the weight of the medical instrument device. That way the medical instrument device remains attached to the hospital pole and due to the flexible biasing apparatuses the device's vibration is suppressed while attached to the hospital pole. | 11-13-2008 |
Patent application number | Description | Published |
20120150123 | INFUSION SET - A single package infusion set is provided, including one or more of the following inserters: pushbutton-type, squeeze-type, contact-type, skin pinching-type, folding retraction-type, or multistage-type inserter having at least one reusable stage. The infusion set further includes adhesion means with user-selectable degrees of adhesion strength, self-sealing tube connection means, a lens feature to view, a site beneath the set, exemplary tube management and connection elements, insulin supply, adhesion concealment means, finger loops on the inserter and site preparation wipes or sprays, optionally provided as part of the inserter. The system further includes a package which may hold a number of easily released sets, retrievable by an inserter, an exemplary insertion needle handle and shroud, an exemplary squeeze-type latch between an upper portion and a lower portion of the set, and/or a tool removable upper portion of the set. | 06-14-2012 |
20120297899 | Chromatography Apparatus And Method - Sample preparation device for receiving in sealing relation one or more filter assemblies and one or more sample containers, each container uniquely positioned within the device to receive filtered sample from a designated filter. The device includes a body, a lid disposed on the body, a container tray, a base, an integrated seal on the body, a valve and a valve actuator. The tray can be disposed in a vacuum chamber defined by the lid and the body, and one or more sample containers can be disposed in the tray. When properly positioned in the tray in the vacuum chamber, each container is in fluid communication with a single respective filter assembly disposed in sealing relation in a respective aperture in the lid. A single actuation of a valve causes the lid to seal to the base and drives the simultaneous filtration of a plurality of samples. | 11-29-2012 |
20140105795 | Chromatography Apparatus And Method - Sample preparation device for receiving in sealing relation one or more filter assemblies and one or more sample containers, each container uniquely positioned within the device to receive filtered sample from a designated filter. The device includes a body, a lid disposed on the body, a container tray, a base, an integrated seal on the body, a valve and a valve actuator. The tray can be disposed in a vacuum chamber defined by the lid and the body, and one or more sample containers can be disposed in the tray. When properly positioned in the tray in the vacuum chamber, each container is in fluid communication with a single respective filter assembly disposed in sealing relation in a respective aperture in the lid. A single actuation of a valve to place the vacuum chamber under vacuum causes the lid to seal to the base and drives the simultaneous filtration of a plurality of samples. | 04-17-2014 |
20140298924 | Chromatography Apparatus And Method - Sample preparation device for receiving in sealing relation one or more filter assemblies and one or more sample containers, each container uniquely positioned within the device to receive filtered sample from a designated filter. The device includes a body, a lid disposed on the body, a container tray, a base, an integrated seal on the body, a valve and a valve actuator. The tray can be disposed in a vacuum chamber defined by the lid and the body, and one or more sample containers can be disposed in the tray. When properly positioned in the tray in the vacuum chamber, each container is in fluid communication with a single respective filter assembly disposed in sealing relation in a respective aperture in the lid. A single actuation of a valve to place the vacuum chamber under vacuum causes the lid to seal to the base and drives the simultaneous filtration of a plurality of samples. | 10-09-2014 |